AR032622A1 - Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos - Google Patents
Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentosInfo
- Publication number
- AR032622A1 AR032622A1 ARP010102840A ARP010102840A AR032622A1 AR 032622 A1 AR032622 A1 AR 032622A1 AR P010102840 A ARP010102840 A AR P010102840A AR P010102840 A ARP010102840 A AR P010102840A AR 032622 A1 AR032622 A1 AR 032622A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkyl
- synthesis
- het
- azepan
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 230000015572 biosynthetic process Effects 0.000 title abstract 4
- 238000003786 synthesis reaction Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- QTLLOLTVQMFWDZ-UHFFFAOYSA-N 4-aminoazepan-3-one Chemical compound NC1CCCNCC1=O QTLLOLTVQMFWDZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000007905 drug manufacturing Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos de 4-amino-azepan-3-ona y sales, hidratos y solvatos farmacéuticamente aceptables de los mismos, que son inhibidores de proteasas, particularmente de cisteína- y serina-proteasas, y por lo tanto son utiles en el tratamiento de enfermedades en las cuales están implicadas dichas proteasas, especialmente trastornos de pérdida excesiva de hueso o cartílago. Dichos compuestos de 4-amino-azepan-3-ona tienen la formula (1), en la que: R1 se selecciona del grupo constituido por las formulas (2), (3) y (4); R2 se selecciona del grupo constituido por alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, R9C(O)-, R9C(S)-, R9SO2-, R9R11NC(O)-, y R9SO2R11NC(O)-; R3 es alquilo C1-6; R4 es R5C(O)-; R5 es Het-alquilo C0-6; R9 se selecciona del grupo constituido por alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; R11 se selecciona del grupo constituido por H, alquilo C1-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R' es H; R'' es H; R''' es H; R'''' se selecciona del grupo constituido por alquilo C1-6, cicloalquil C3-6-alquilo C0-6, alquenilo C2-6, alquinilo C2-6, Het-alquilo C0-6, y Ar-alquilo C0-6; n es un numero entero de 1 a 5. Además, se dan a conocer: composiciones farmacéuticas que comprenden dichos compuestos, intermediarios utiles en la síntesis de tales compuestos, un procedimiento para la síntesis de dichos compuestos, y el uso de tales compuestos en la fabricacion de medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59384500A | 2000-06-14 | 2000-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032622A1 true AR032622A1 (es) | 2003-11-19 |
Family
ID=24376433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102840A AR032622A1 (es) | 2000-06-14 | 2001-06-14 | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1307204A4 (es) |
| JP (1) | JP2004503502A (es) |
| KR (1) | KR20030008220A (es) |
| CN (1) | CN1444481A (es) |
| AP (1) | AP2002002671A0 (es) |
| AR (1) | AR032622A1 (es) |
| AU (1) | AU2001268407A1 (es) |
| BG (1) | BG107327A (es) |
| BR (1) | BR0111693A (es) |
| CA (1) | CA2412353A1 (es) |
| CZ (1) | CZ20024086A3 (es) |
| EA (1) | EA200300018A1 (es) |
| EC (1) | ECSP024388A (es) |
| HU (1) | HUP0301231A2 (es) |
| IL (1) | IL153421A0 (es) |
| MA (1) | MA25758A1 (es) |
| MX (1) | MXPA02012442A (es) |
| NO (1) | NO20025786L (es) |
| NZ (1) | NZ522965A (es) |
| OA (1) | OA12288A (es) |
| PE (1) | PE20011374A1 (es) |
| PL (1) | PL360508A1 (es) |
| SK (1) | SK17592002A3 (es) |
| WO (1) | WO2001095911A1 (es) |
| ZA (1) | ZA200209808B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034159A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| HUP0301964A3 (en) * | 2000-11-22 | 2007-09-28 | Smithkline Beecham Corp | Protease inhibitors |
| US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
| WO2002066035A2 (en) | 2001-02-20 | 2002-08-29 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| US20040157828A1 (en) * | 2001-05-17 | 2004-08-12 | Ren Xie | Protease inhibitors |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| EP1653944B1 (en) * | 2003-08-01 | 2010-11-10 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| JP4773960B2 (ja) | 2003-08-01 | 2011-09-14 | 中外製薬株式会社 | マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノグアニジン型アゾール化合物 |
| ES2309563T3 (es) | 2003-08-01 | 2008-12-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos de piperidina utiles como inhibidores de malonil coenzima a descarboxilasa. |
| WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
| CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
| US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| TR200101869T2 (tr) * | 1998-12-23 | 2002-01-21 | Smithkline Beecham Corporation | Proteaz İnhibitörleri. |
| JP2003513956A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2004509083A (ja) * | 2000-09-01 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | 治療方法 |
| HUP0301964A3 (en) * | 2000-11-22 | 2007-09-28 | Smithkline Beecham Corp | Protease inhibitors |
| US20040157828A1 (en) * | 2001-05-17 | 2004-08-12 | Ren Xie | Protease inhibitors |
-
2001
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/pt not_active IP Right Cessation
- 2001-06-14 PL PL36050801A patent/PL360508A1/xx not_active Application Discontinuation
- 2001-06-14 EA EA200300018A patent/EA200300018A1/ru unknown
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/sk not_active Application Discontinuation
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/es not_active Application Discontinuation
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/ja active Pending
- 2001-06-14 IL IL15342101A patent/IL153421A0/xx unknown
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
- 2001-06-14 CN CN01813500A patent/CN1444481A/zh active Pending
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en not_active Ceased
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/cs unknown
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/es unknown
- 2001-06-14 AR ARP010102840A patent/AR032622A1/es not_active Application Discontinuation
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/hu unknown
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/ko not_active Withdrawn
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/bg unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/es unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004503502A (ja) | 2004-02-05 |
| EP1307204A4 (en) | 2004-06-02 |
| NZ522965A (en) | 2004-06-25 |
| OA12288A (en) | 2003-12-12 |
| CA2412353A1 (en) | 2001-12-20 |
| BR0111693A (pt) | 2004-04-06 |
| WO2001095911A1 (en) | 2001-12-20 |
| IL153421A0 (en) | 2003-07-06 |
| SK17592002A3 (sk) | 2003-05-02 |
| PL360508A1 (en) | 2004-09-06 |
| CZ20024086A3 (cs) | 2003-05-14 |
| BG107327A (bg) | 2003-07-31 |
| NO20025786L (no) | 2003-02-12 |
| KR20030008220A (ko) | 2003-01-24 |
| EA200300018A1 (ru) | 2003-06-26 |
| EP1307204A1 (en) | 2003-05-07 |
| ZA200209808B (en) | 2004-07-09 |
| PE20011374A1 (es) | 2002-04-07 |
| AU2001268407A1 (en) | 2001-12-24 |
| HUP0301231A2 (hu) | 2003-08-28 |
| ECSP024388A (es) | 2003-02-06 |
| CN1444481A (zh) | 2003-09-24 |
| AP2002002671A0 (en) | 2002-12-31 |
| MXPA02012442A (es) | 2003-04-25 |
| NO20025786D0 (no) | 2002-12-02 |
| MA25758A1 (fr) | 2003-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032877A1 (es) | Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| DOP2001000271A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes antiinflamatorios y analgésicos. | |
| BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
| MEP9509A (en) | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| AR032622A1 (es) | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos | |
| AR035792A1 (es) | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo | |
| SE0104332D0 (sv) | Therapeutic agents | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| DE60132309D1 (de) | Amin-derivate zur behandlung von apoptosis | |
| PT1263724E (pt) | Novos compostos | |
| PA8529501A1 (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7." | |
| AR003440A1 (es) | Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados. | |
| ES2123039T3 (es) | Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| ATE401056T1 (de) | Formoterol und ciclesonid aerosol-formulierungen | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| UY27593A1 (es) | Nuevos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |